UroGen Pharma Ltd. (URGN): Capital Expenditures
$289.0K
Year ended 2025-12-31
$218.0K
Trailing 12 months to 2026-06-30
+4.4%
3-year compound annual growth
-25.0%
5-year compound annual growth
-0.4%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $289.0K | -2.0% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $295.0K | +52.1% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $194.0K | -23.6% | 2025-03-10, From 2023-01-01 |
| 2022-12-31 | $254.0K | -66.2% | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | $752.0K | -38.1% | 2023-03-24, From 2021-01-01 |
| 2020-12-31 | $1.22M | +273.8% | 2022-03-21, From 2020-01-01 |
| 2019-12-31 | $325.0K | -42.0% | 2021-03-18, From 2019-01-01 |
| 2018-12-31 | $560.0K | +106.6% | 2020-03-02, From 2018-01-01 |
| 2017-12-31 | $271.0K | -61.0% | 2020-03-02, From 2017-01-01 |
| 2016-12-31 | $695.0K | +130.9% | 2019-02-28, From 2016-01-01 |
| 2015-12-31 | $301.0K | n/a | 2018-03-15, From 2015-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | 2025-12-31 | $289.0K | -2.0% |
| Zevra Therapeutics, Inc. (ZVRA) | 2025-12-31 | $835.0K | n/a |
| Zymeworks Inc. (ZYME) | 2025-12-31 | $1.52M | -23.6% |
| Gyre Therapeutics, Inc. (GYRE) | 2025-12-31 | $1.19M | -48.6% |
| Xencor Inc (XNCR) | 2025-12-31 | $3.15M | -48.3% |
| Lifecore Biomedical, Inc. (LFCR) | 2025-05-25 | $13.41M | -27.1% |
| Cytokinetics Inc (CYTK) | 2025-12-31 | $24.81M | +535.1% |
| Standard Biotools Inc. (LAB) | 2025-12-31 | $8.30M | -0.6% |
| ARS Pharmaceuticals, Inc. (SPRY) | 2025-12-31 | $339.0K | -39.8% |
Compare URGN, ZVRA, ZYME, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗